Yu-Ling Miao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu-Ling Miao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Jian Ding
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica
1 shared publication- Jin-Xue He
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
1 shared publication Li-Na Zhou
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica
1 shared publicationShan-Shan Song
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica
1 shared publicationXia-Juan Huan
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica
1 shared publicationXu-Bin Bao
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (7) , e202503589
UBA3 reduction sensitizes cancer cells to NAE inhibitors
The NEDD8-activating enzyme (NAE), comprising NAE1 and UBA3, is an anticancer target. The relative contribution of each of these subunits toward NAE inhibitor (NAEi) efficacy remains unclear. We demonstrated a profound interdependence of NAE1 and UBA3 expression. UBA3 reduction augmented NAEi sensitivity, whereas its overexpression led to decreased sensitivity. UBA3 deficiency enhanced RKO xenograft sensitivity to SOMCL-19-133 (NAEi), which was reversed by UBA3 restoration. Cells with naturally low UBA3 expression were highly NAEi-sensitive. The criticality of UBA3 in NAEi sensitivity is not completely unexpected given that the ability of NAEi to directly bind to UBA3 is known. TCGA data showed that rectum adenocarcinoma patients with low UBA3 mRNA had poorer prognoses, and 27.16% of tumors expressed low UBA3 mRNA. We propose that low UBA3 expression may serve as a NAEi sensitivity biomarker, particularly given that MLN4924 (NAEi) phase 3 failures may be due to a lack of patient stratification. Therefore, our key findings, on the criticality of UBA3 in NAEi sensitivity, underpin future clinical evaluations.
- 29 April 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (7) , e202503589
Open AccessUBA3 reduction sensitizes cancer cells to NAE inhibitors
The NEDD8-activating enzyme (NAE), comprising NAE1 and UBA3, is an anticancer target. The relative contribution of each of these subunits toward NAE inhibitor (NAEi) efficacy remains unclear. We demonstrated a profound interdependence of NAE1 and UBA3 expression. UBA3 reduction augmented NAEi sensitivity, whereas its overexpression led to decreased sensitivity. UBA3 deficiency enhanced RKO xenograft sensitivity to SOMCL-19-133 (NAEi), which was reversed by UBA3 restoration. Cells with naturally low UBA3 expression were highly NAEi-sensitive. The criticality of UBA3 in NAEi sensitivity is not completely unexpected given that the ability of NAEi to directly bind to UBA3 is known. TCGA data showed that rectum adenocarcinoma patients with low UBA3 mRNA had poorer prognoses, and 27.16% of tumors expressed low UBA3 mRNA. We propose that low UBA3 expression may serve as a NAEi sensitivity biomarker, particularly given that MLN4924 (NAEi) phase 3 failures may be due to a lack of patient stratification. Therefore, our key findings, on the criticality of UBA3 in NAEi sensitivity, underpin future clinical evaluations.